4.0 Article

Patient Experience of Antimuscarinic Treatment for Overactive Bladder: A Qualitative Exploration of Online Forum Content

Journal

FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY
Volume 28, Issue 3, Pages E49-E54

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/SPV.0000000000001156

Keywords

antimuscarinic; overactive bladder; qualitative analysis; patient satisfaction

Ask authors/readers for more resources

This study qualitatively explores the patient experience of antimuscarinic medications for overactive bladder through a content analysis of user reviews on Drugs.com. The results indicate important differences in side effects and patient satisfaction within this class of medications. Symptom improvement was found to be the leading factor for patient satisfaction, while gastrointestinal side effects were associated with dissatisfaction.
Importance Antimuscarinic medications are often discontinued, and there is a paucity of data regarding patient experience of medications within this class. Objective The objective of this study is to qualitatively explore patient experience of antimuscarinic medications used for overactive bladder using reviews on Drugs.com. Study Design We examined reviews prior to February 2, 2020 (available since 2008) for oral antimuscarinic medications. User content was reviewed qualitatively via inductive content analysis. Investigators coded third-party impressions, categorizing each review as positive, mostly positive, mostly negative, or negative. The prevalence of side effects, themes, and impressions are described, with comparisons by drug using chi(2), Mann-Whitney U, and Kruskal-Wallis tests, as appropriate. Correlation between ordinal and categorical variables was performed using Tau and Spearman correlation coefficients, respectively. Results We analyzed 469 user reviews. 68.2% reported symptom improvement. The most common side effects were dry mouth (29%) and fatigue (10.7%). Fewer neurologic side effects were reported in the solifenacin (13.9%) and trospium (none) groups (P = 0.009). Tolterodine and trospium immediate release had lower rates of ears, nose, and throat side effects (22.5% and 26.2%, respectively, P = 0.001.) Analysis of themes suggested 2 domains driving overall satisfaction: improvement and side effects. Improvement was associated with a positive satisfaction score (rho = 0.64, P < 0.001) and gestalt impression (rho = 0.74, P < 0.001). The factors that most negatively affected these measures were persistent symptoms followed by gastrointestinal side effects (P < 0.001). Conclusions Our data suggest important differences within this class of medication both in terms of side effects and patient satisfaction. Furthermore, symptom improvement is the leading factor for patient satisfaction, whereas gastrointestinal side effects are associated with dissatisfaction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available